News

PharmExec21h
Roche’s Next-Gen Bispecific Antibody Shows Early Promise in Hemophilia A
Early results from the Phase I/II NXTAGE trial show that NXT007 may achieve hemostatic normalization in patients with ...
The Pharma Letter1d
Roche’s Hemlibra successor moves to Phase III
Swiss pharma giant Roche has announced positive Phase I/II data on NXT007 in people with hemophilia A, supporting its ...
Pharmabiz1d
Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress
Chugai Pharma presents positive data from NXTAGE phase I/II study of NXT007 in people with haemophilia A at ISTH 2025 Congress: Tokyo Tuesday, June 24, 2025, 13:00 Hrs [IST] Chuga ...
pharmaphorum2d
Roche's Hemlibra follow-up set for phase 3 in haemophilia A
The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...
Early data suggest Roche’s NXT007 may have the potential to provide haemostatic normalisation in people with haemophilia A
Positive phase I/II data presented at the 2025 International Society on Thrombosis and Haemostasis (ISTH) Congress show ...